DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Black, A. E.
Right arrow Articles by Woolf, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Black, A. E.
Right arrow Articles by Woolf, T. F.

Vol. 27, Issue 8, 916-923, August 1999

Metabolism and Excretion of Atorvastatin in Rats And Dogs

Ann E. Black, Roger N. Hayes, Bruce D. Roth, Peter Woo, and Thomas F. Woolf

Departments of Pharmacokinetics, Dynamics, and Metabolism (A.E.B., R.N.H., T.F.W.) and Chemistry (B.D.R., P.W.), Parke-Davis Pharmaceutical Research Co., Ann Arbor, Michigan

Atorvastatin (AT) is a second-generation potent inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, clinically approved for lowering plasma cholesterol. Using a mixture of [D5/D0] AT and/or [14C]AT, the metabolic fate and excretion of AT were examined in rats and dogs following single and multiple oral doses. Limited biliary recycling was examined in one dog after a single dose of AT. AT-derived metabolites in bile samples were identified by metabolite screening of the [D5/D0] AT molecular clusters using tandem mass spectrometry. Bile was a major route of [14C] drug-derived excretion, accounting for 73 and 33% of the oral dose in the rat and dog, respectively. The remaining radioactivity was recovered in the feces; only trace amounts were excreted in urine. Radioactive components identified in rat and dog bile were the para- and ortho-hydroxy metabolites, a glucuronide conjugate of ortho-hydroxy AT, and unchanged AT. Two minor radioactive components were identified as beta -oxidation products of AT with one confirmed as a beta -oxidized AT derivative. The reappearance of AT and major metabolites in bile from a dog administered a sample of its previously excreted bile indicated biliary recycling is an important component in AT metabolism. Multiple dose administration in rats did not alter biliary metabolic profiles. Rat and dog plasma profiles after multiple dose administration were similar and showed no additional metabolites not found in bile. Examination of rat and dog bile and plasma indicates that AT primarily undergoes oxidative metabolism.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
C. S. Madsen, E. Janovitz, R. Zhang, Van Nguyen-Tran, C. S. Ryan, X. Yin, H. Monshizadegan, M. Chang, C. D'Arienzo, S. Scheer, et al.
The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 576 - 586.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet
PHARMACOKINETICS OF ATORVASTATIN AND ITS HYDROXY METABOLITES IN RATS AND THE EFFECTS OF CONCOMITANT RIFAMPICIN SINGLE DOSES: RELEVANCE OF FIRST-PASS EFFECT FROM HEPATIC UPTAKE TRANSPORTERS, AND INTESTINAL AND HEPATIC METABOLISM
Drug Metab. Dispos., July 1, 2006; 34(7): 1175 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet
Multiple Transporters Affect the Disposition of Atorvastatin and Its Two Active Hydroxy Metabolites: Application of in Vitro and ex Situ Systems
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 762 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Li, R. Subramanian, S. Yu, and T. Prueksaritanont
ACYL-COENZYME A FORMATION OF SIMVASTATIN IN MOUSE LIVER PREPARATIONS
Drug Metab. Dispos., January 1, 2006; 34(1): 102 - 110.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
L. Zhang, Z. G. Zhang, G. L. Ding, Q. Jiang, X. Liu, H. Meng, A. Hozeska, C. Zhang, L. Li, D. Morris, et al.
Multitargeted Effects of Statin-Enhanced Thrombolytic Therapy for Stroke With Recombinant Human Tissue-Type Plasminogen Activator in the Rat
Circulation, November 29, 2005; 112(22): 3486 - 3494.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Prueksaritanont, R. Subramanian, X. Fang, B. Ma, Y. Qiu, J. H. Lin, P. G. Pearson, and T. A. Baillie
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
Drug Metab. Dispos., May 1, 2002; 30(5): 505 - 512.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Prueksaritanont, B. Ma, X. Fang, R. Subramanian, J. Yu, and J. H. Lin
beta -Oxidation of Simvastatin in Mouse Liver Preparations
Drug Metab. Dispos., October 1, 2001; 29(10): 1251 - 1255.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.